Page 337 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

64. van Staveren MC, van Kuilenburg ABP, Guchelaar HJ, et al. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. Br J Clin Pharmacol. 2016;81(3):553-561.
65. MeulendijksD,HenricksLM,JacobsBAW,etal.Pretreatmentserumuracilconcentrationasapredictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-1424.
66. Jacobs BAW, Rosing H, de Vries N, et al. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm
Biomed Anal. 2016;126:75-82.
67. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation
of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
Pharmacogenomics J. 2013;13(5):389-395.
68. Hsiao H-H, Lin S-F. Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency.
Current Pharmacogenomics. 2007;5(1):31-38.
69. Duley JA, Ni M, Shannon C, et al. Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic
data for thymine and two sequential metabolites following oral thymine administration to
healthy adult males. Eur J Pharm Sci. 2016;81:36-41.
70. Watanabe A, Yang CC, Cheung WY. Association of baseline patient characteristics with adjuvant
chemotherapy toxicities in stage III colorectal cancer patients. Med Oncol. 2018;35(10):125.
71. Meulendijks D, van Hasselt JGC, Huitema ADR, et al. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer. 2016;54:120-130.
72. Cassidy J, Twelves C, Van CE, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann
Oncol. 2002;13(4):566-575.
73. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent
predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75(1):11-17.
74. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of
5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264-3268.
75. Naughton M. Evolution of capecitabine dosing in breast cancer. Clin Breast Cancer. 2010;10(2):130-
135.
76. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional
analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase
activity. Cancer Res. 2014;74(9):2545-2554.
77. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant
colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12).
78. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism
in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5886-5892.
79. Elraiyah T, Jerde CR, Shrestha S, et al. Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol
Ther. 2017;101(3):382-390.
80. Hamzic S, Amstutz U, Largiader CR. Come a long way, still a ways to go: from predicting and
preventing fluoropyrimidine toxicity to increased efficacy? Pharmacogenomics. 2018;19(8):689- 692.
13
General discussion
335